Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

General Inclusion Criteria:

Diagnosis of 1 of the following tumor types:

Melanoma (cutaneous).
NSCLC.
SCCHN (oral, oropharyngeal, hypopharyngeal, or laryngeal).
Urothelial carcinoma.
Renal cell carcinoma (Part B only).
Understand the study, be willing to comply with all study procedures and sign the informed consent
Adequate tumor tissue available
ECOG performance status of 0 or 1
Negative pregnancy test (females of childbearing potential)
Agree to use of contraception during the study until at least 90 days after final GEN-009 dose
Adequate hematologic, liver, and kidney function

Part A-specific Inclusion:

Have completed or will complete treatment for their disease with curative intent
Have no evidence of disease

Part B-specific Inclusion:

Receiving or will initiate treatment with nivolumab or pembrolizumab per disease as listed below:

NSCLC: Patients with metastatic non-squamous NSCLC beginning first-line pembrolizumab in combination with pemetrexed and platinum chemotherapy, or metastatic squamous NSCLC beginning first-line pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel
SCCHN: Patients beginning pembrolizumab with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy, or beginning first-line pembrolizumab for recurrent or metastatic SCCHN if tumors express PD-L1 with a Combined Positive Score (CPS) ≥ 1.
Cutaneous Melanoma: Patients with unresectable or metastatic cutaneous melanoma beginning nivolumab monotherapy or nivolumab in combination with ipilimumab.

Urothelial Carcinoma: Patients with locally advanced or metastatic urothelial carcinoma who are beginning pembrolizumab who:

Are not eligible for cisplatin-containing chemotherapy, and tumor is PD-L1 positive with CPS ≥ 10, or are not eligible for any platinum-containing chemotherapy, OR
Have had disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Renal Cell Carcinoma:

Patients with advanced RCC who have received prior anti-angiogenic therapy, and are beginning nivolumab monotherapy, OR
Untreated patients with intermediate or poor risk RCC based on the IMDC score who are beginning nivolumab in combination with ipilimumab.
Disease assessment by CT or MRI
Have at least 1 lesion that is measureable by RECIST 1.1
Agree to a tumor biopsy 50 days after first GEN-009 vaccination
Participants with hypothyroidism must be on thyroid replacement treatment

General Exclusion Criteria:

Received a live vaccine ≤ 28 days, or a non-live vaccine ≤ 14 days, prior to the first dose of GEN-009
Acute or chronic skin disorders that would interfere with injection
Receiving immunosuppressive therapies or systemic corticosteroids. Note: Use of topical corticosteroids or inhaled corticosteroids is acceptable
Allergy to the vaccine adjuvant Hiltonol (poly-ICLC)
Active hepatitis B or hepatitis C infection
HIV Positive
History of clinically significant cardiac condition
History of leptomeningeal carcinomatosis
Had clinically active immune-mediated disease within 5 years
Received a prior allogeneic stem cell transplant
Has primary immune deficiency
Received a prior solid organ transplant
Has malignant disease, other than the tumor types being treated in this study
Female patient who is pregnant, breastfeeding, or who plans to become pregnant from the signing of the informed consent until ≥ 90 days from last dose of GEN-009
Any condition that in the judgment of the PI would make the patient inappropriate for enrollment in the study
Patient has received cytotoxic chemotherapy within 4 weeks of the first leukapheresis

Part A-specific Exclusion Criteria:

Has received or requires more than 2 adjuvant or neoadjuvant regimens (other than surgical excisions) given with curative intent prior to first GEN-009 vaccination
Has not recovered or stabilized from any clinically significant toxicity associated with any prior procedure or anticancer therapy